FRA:RHO - Deutsche Boerse Ag - CH0012032113 - Common Stock - Currency: EUR
FRA:RHO (5/14/2025, 7:00:00 PM)
286
-4.2 (-1.45%)
The current stock price of RHO.DE is 286 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 54.56 | 640.37B | ||
LLY.DE | ELI LILLY & CO | 52.33 | 614.20B | ||
ZEG.DE | ASTRAZENECA PLC | 17.91 | 369.25B | ||
1JNJ.MI | JOHNSON & JOHNSON | 15.42 | 335.84B | ||
JNJ.DE | JOHNSON & JOHNSON | 14.5 | 315.39B | ||
NOV.DE | NOVO NORDISK A/S-B | 18.8 | 257.07B | ||
SAN.PA | SANOFI | 13.2 | 217.49B | ||
SNW.DE | SANOFI | 13.2 | 217.46B | ||
1SAN.MI | SANOFI | 13.15 | 216.65B | ||
NOT.DE | NOVARTIS AG-REG | 12.73 | 187.57B | ||
6MK.DE | MERCK & CO. INC. | 9.57 | 168.85B | ||
1PFE.MI | PFIZER INC | 7.07 | 115.87B |
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
ROCHE HOLDING AG-BR
Grenzacherstrasse 124
Basel BASEL-STADT CH
Employees: 103249
The current stock price of RHO.DE is 286 EUR. The price decreased by -1.45% in the last trading session.
The exchange symbol of ROCHE HOLDING AG-BR is RHO and it is listed on the Deutsche Boerse Ag exchange.
RHO.DE stock is listed on the Deutsche Boerse Ag exchange.
27 analysts have analysed RHO.DE and the average price target is 345.52 EUR. This implies a price increase of 20.81% is expected in the next year compared to the current price of 286. Check the ROCHE HOLDING AG-BR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ROCHE HOLDING AG-BR (RHO.DE) has a market capitalization of 231.45B EUR. This makes RHO.DE a Mega Cap stock.
ROCHE HOLDING AG-BR (RHO.DE) currently has 103249 employees.
The Revenue of ROCHE HOLDING AG-BR (RHO.DE) is expected to grow by 4.26% in the next year. Check the estimates tab for more information on the RHO.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ROCHE HOLDING AG-BR (RHO.DE) has a dividend yield of 3.73%. The yearly dividend amount is currently 10.8. Check the full fundamental report for a detailed analysis of RHO.DE dividend history, reliability and sustainability.
ROCHE HOLDING AG-BR (RHO.DE) will report earnings on 2025-07-24.
The PE ratio for ROCHE HOLDING AG-BR (RHO.DE) is 14.24. This is based on the reported non-GAAP earnings per share of 20.09 and the current share price of 286 EUR. Check the full fundamental report for a full analysis of the valuation metrics for RHO.DE.
ChartMill assigns a technical rating of 2 / 10 to RHO.DE.
ChartMill assigns a fundamental rating of 6 / 10 to RHO.DE. Both the health and profitability get an excellent rating, making RHO.DE a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months RHO.DE reported a non-GAAP Earnings per Share(EPS) of 20.09. The EPS increased by 1.24% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 13.68% | ||
ROA | 8.13% | ||
ROE | 26.06% | ||
Debt/Equity | 0.98 |
ChartMill assigns a Buy % Consensus number of 71% to RHO.DE. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of 10.74% and a revenue growth 4.26% for RHO.DE